ZUG, Switzerland—Oculis Holding AG (Nasdaq: OCS / XICE: OCS), a global biopharmaceutical company focused on addressing ophthalmic and neuro-ophthalmic diseases, announced results for the first quarter ended March 31, 2026, and provided an update on the company’s progress. For the quarter, Oculis reported held cash, cash equivalents and short-term investments of $277.6 million, compared with $268.7 million as of December 31, 2025. The increase in cash, cash equivalents, and short-term investments was primarily due to proceeds received from sales under the company’s existing at-the-market offering program during the quarter, offset by planned operating expenses, the company noted.